跳至主要内容
临床试验/NCT00276042
NCT00276042已完成2 期

Prospective, Randomized, Investigator-Blind Trial to Evaluate the Bacteriologic Eradication, Safety and Tolerability, and Pharmacokinetics of Different Dosages of Faropenem Medoxomil BID for 10 Days in the Treatment of Acute Otitis Media

Replidyne3 个研究点 分布在 2 个国家目标入组 328 人开始时间: 2006年1月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
328
试验地点
3
主要终点
To evaluate bacteriologic efficacy

研究概览

简要总结

The study will be conducted in infants and children with acute otitis media, 6 months to less than 7 years old, in Costa Rica and Israel. The primary objective of this trial will be to describe bacteriologic efficacy in those with initial culture positive specimens with different dosages of faropenem

详细描述

The study will be conducted in infants and children with acute otitis media, 6 months to <7 years old, in Costa Rica and Israel. Faropenem is to be used as therapy for both simple and complicated AOM.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
6 Months 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Acute Otis Media

排除标准

  • Any antibiotic for more than 24 hours (unless a treatment failure) within 7 days prior to enrollment

结局指标

主要结局

To evaluate bacteriologic efficacy

次要结局

  • To describe investigator assessment of clinical response

研究者

发起方
Replidyne
申办方类型
Industry

研究点 (3)

Loading locations...

相似试验